These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22781398)

  • 1. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
    Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
    Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
    Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
    Zhang C; Guo F; Xu G; Ma J; Shao F
    Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
    Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
    Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition.
    Yu J; Zhang W; Gao F; Liu YX; Chen ZY; Cheng LY; Xie SF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2014 Apr; 13(2):184-91. PubMed ID: 24686546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma.
    Dai X; Ahn KS; Wang LZ; Kim C; Deivasigamni A; Arfuso F; Um JY; Kumar AP; Chang YC; Kumar D; Kundu GC; Magae J; Goh BC; Hui KM; Sethi G
    Mol Cancer Ther; 2016 Dec; 15(12):2966-2976. PubMed ID: 27765853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma.
    Tanaka S; Shiraha H; Nakanishi Y; Nishina S; Matsubara M; Horiguchi S; Takaoka N; Iwamuro M; Kataoka J; Kuwaki K; Hagihara H; Toshimori J; Ohnishi H; Takaki A; Nakamura S; Nouso K; Yagi T; Yamamoto K
    Int J Cancer; 2012 Dec; 131(11):2537-46. PubMed ID: 22488108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
    Yang L; Chang Y; Cao P
    Exp Cell Res; 2018 Oct; 371(1):231-237. PubMed ID: 30107147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
    Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
    Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 11. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
    Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 activation mediates epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells.
    Zhang CH; Guo FL; Xu GL; Jia WD; Ge YS
    Hepatogastroenterology; 2014 Jun; 61(132):1082-9. PubMed ID: 26158169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
    Yu M; Han G; Qi B; Wu X
    Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells.
    Gao Y; Li W; Liu R; Guo Q; Li J; Bao Y; Zheng H; Jiang S; Hua B
    Oncol Rep; 2017 Aug; 38(2):1224-1232. PubMed ID: 28677802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
    Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
    J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
    Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma.
    Asano T; Yamada S; Fuchs BC; Takami H; Hayashi M; Sugimoto H; Fujii T; Tanabe KK; Kodera Y
    Int J Oncol; 2017 May; 50(5):1647-1654. PubMed ID: 28350091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma.
    Pan JX; Wang F; Ye LY
    Biochem Biophys Res Commun; 2016 Oct; 479(4):610-614. PubMed ID: 27697528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
    Long L; Xiang H; Liu J; Zhang Z; Sun L
    Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
    Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
    Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.